美國(guó)ZymoGenetics www.zymogenetics.com
ZymoGenetics總部設(shè)在西雅圖市，其開(kāi)發(fā)的藥物包括人造血管凝乳酶Recothrom，主要用于手術(shù)時(shí)防止失血過(guò)多。
2010年百時(shí)美施貴寶8.85億美元收購(gòu)ZymoGenetics

Founded in 1981, ZymoGenetics is a biopharmaceutical company with a development pipeline of proteins, antibodies, and antibody-like molecules. ZymoGenetics is publicly traded (NASDAQ: ZGEN) and headquartered in Seattle, Washington in the historic Seattle City Light Steam Plant building.
Our mission is to create novel protein drugs that will significantly help patients fight their diseases. We have contributed to the discovery or development of six recombinant protein products now marketed by other companies. Current programs target inflammatory and autoimmune diseases, bleeding, cancer and viral indications. Our first internally developed product, RECOTHROM® Thrombin, topical (Recombinant), was approved by the U.S. Food and Drug Administration (FDA) on January 17, 2008 for use as a topical hemostat to control moderate bleeding during surgical procedures and is now marketed in the United States. We have a rich pipeline of novel therapeutics, which we are developing on our own or in collaboration with partners.
In 2009, our strategic objectives are:
Capitalize the RECOTHROM® market opportunity Our goal is to build on the 4Q 2008 sales momentum to achieve sales in the range of $25-35 million dollars. 
Aggressively develop PEG-Interferon lambda with partner Bristol-Myers Squibb Our goal is to complete the ongoing Phase 1b clinical trials and initiate the first Phase 2 clinical trial. We expect to receive $200 million in cash through a combination of license fees and milestones during 2009, of which $95 million is related to the start of Phase 2 clinical trials. 
Reduce cash usage through additional cost cutting and partnering activities Our goal is to complete a partnering transaction to facilitate more rapid movement of our preclinical assets into development and to bring additional cash into the company. In addition, we are committed to reducing cash consumption and making operations more efficient. 
ZymoGenetics is an emerging leader among biopharmaceutical companies.